JP2014501526A - アッセイ法 - Google Patents
アッセイ法 Download PDFInfo
- Publication number
- JP2014501526A JP2014501526A JP2013545486A JP2013545486A JP2014501526A JP 2014501526 A JP2014501526 A JP 2014501526A JP 2013545486 A JP2013545486 A JP 2013545486A JP 2013545486 A JP2013545486 A JP 2013545486A JP 2014501526 A JP2014501526 A JP 2014501526A
- Authority
- JP
- Japan
- Prior art keywords
- assay
- haptoglobin
- assay method
- reagent
- hemoglobin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003556 assay Methods 0.000 title claims description 107
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 97
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 67
- 230000000694 effects Effects 0.000 claims abstract description 57
- 102000014702 Haptoglobin Human genes 0.000 claims abstract description 54
- 108050005077 Haptoglobin Proteins 0.000 claims abstract description 54
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 42
- 102000013415 peroxidase activity proteins Human genes 0.000 claims abstract description 38
- 108040007629 peroxidase activity proteins Proteins 0.000 claims abstract description 38
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 36
- 108010071602 haptoglobin-hemoglobin complex Proteins 0.000 claims abstract description 24
- 239000000872 buffer Substances 0.000 claims abstract description 17
- 239000000758 substrate Substances 0.000 claims abstract description 17
- 230000008859 change Effects 0.000 claims abstract description 11
- 239000011541 reaction mixture Substances 0.000 claims abstract description 9
- 238000012207 quantitative assay Methods 0.000 claims abstract description 6
- 230000003287 optical effect Effects 0.000 claims abstract description 4
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 229940088598 enzyme Drugs 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical group SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 12
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 claims description 11
- 108010015776 Glucose oxidase Proteins 0.000 claims description 11
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- 230000003196 chaotropic effect Effects 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 claims description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- BYMZHAPPSICVQH-UHFFFAOYSA-N 2-amino-4-hydroxybenzenesulfonic acid Chemical compound NC1=CC(O)=CC=C1S(O)(=O)=O BYMZHAPPSICVQH-UHFFFAOYSA-N 0.000 claims description 3
- -1 3-aminophenozone Chemical compound 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 claims description 2
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 claims description 2
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 claims description 2
- UHBAPGWWRFVTFS-UHFFFAOYSA-N 4,4'-dipyridyl disulfide Chemical compound C=1C=NC=CC=1SSC1=CC=NC=C1 UHBAPGWWRFVTFS-UHFFFAOYSA-N 0.000 claims description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 claims description 2
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003833 bile salt Substances 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001912 dicoumarol Drugs 0.000 claims description 2
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 claims description 2
- 229940116357 potassium thiocyanate Drugs 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- NMWCVZCSJHJYFW-UHFFFAOYSA-M sodium;3,5-dichloro-2-hydroxybenzenesulfonate Chemical compound [Na+].OC1=C(Cl)C=C(Cl)C=C1S([O-])(=O)=O NMWCVZCSJHJYFW-UHFFFAOYSA-M 0.000 claims description 2
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 claims description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000008363 phosphate buffer Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 10
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 9
- 239000004366 Glucose oxidase Substances 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 229940116332 glucose oxidase Drugs 0.000 description 9
- 235000019420 glucose oxidase Nutrition 0.000 description 9
- 239000007979 citrate buffer Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 229920000136 polysorbate Polymers 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 108010001073 oxyhemoglobin oxidase Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000012888 bovine serum Substances 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 239000000126 substance Chemical group 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 238000008458 Glucose Oxidase Reagent Methods 0.000 description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 229960003500 triclosan Drugs 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241001135893 Themira Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/725—Haemoglobin using peroxidative activity
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1021509.3 | 2010-12-20 | ||
| GBGB1021509.3A GB201021509D0 (en) | 2010-12-20 | 2010-12-20 | Assay method |
| PCT/GB2011/001731 WO2012085497A1 (en) | 2010-12-20 | 2011-12-19 | Assay method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501526A true JP2014501526A (ja) | 2014-01-23 |
| JP2014501526A5 JP2014501526A5 (enExample) | 2015-02-12 |
Family
ID=43598612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013545486A Pending JP2014501526A (ja) | 2010-12-20 | 2011-12-19 | アッセイ法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130337481A1 (enExample) |
| EP (1) | EP2656082A1 (enExample) |
| JP (1) | JP2014501526A (enExample) |
| CN (1) | CN103492881A (enExample) |
| GB (1) | GB201021509D0 (enExample) |
| WO (1) | WO2012085497A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3031593B1 (fr) * | 2015-01-13 | 2019-05-03 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Analyse du phenol en phase liquide |
| CN104749153A (zh) * | 2015-04-16 | 2015-07-01 | 安徽农业大学 | 一种利用血清氧化巯基的性质诊断肝病的方法和试剂盒 |
| CN105498874B (zh) * | 2016-01-29 | 2017-05-24 | 中国农业大学 | 检测过氧化物酶浓度的芯片、系统、方法及芯片制作方法 |
| CN107966567B (zh) * | 2017-11-21 | 2018-12-18 | 浙江夸克生物科技有限公司 | 一种触珠蛋白测定试剂盒 |
| CN110779914B (zh) * | 2019-11-05 | 2022-05-20 | 湖南科技大学 | 基于血红蛋白与四碳或五碳二元酸复合物试剂盒制备方法 |
| CN112903627B (zh) * | 2021-03-06 | 2023-01-24 | 中国烟草总公司郑州烟草研究院 | 一种在线判定烟草加工过程生物酶活性的方法 |
| CN113372253B (zh) * | 2021-06-11 | 2024-12-06 | 吉林基蛋生物科技有限公司 | 一种胆红素的提取方法及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5954962A (ja) * | 1982-09-22 | 1984-03-29 | Fuji Photo Film Co Ltd | 多層分析材料 |
| JPS62192663A (ja) * | 1986-02-20 | 1987-08-24 | Fuji Photo Film Co Ltd | 免疫反応物定量用多層分析要素 |
| US6251621B1 (en) * | 1993-04-14 | 2001-06-26 | Litmus Concepts, Inc. | Reporter enzyme release technology: methods of assaying for the presence of aspartic proteases and other hydrolytic enzyme activities |
| JP2001523003A (ja) * | 1997-11-12 | 2001-11-20 | ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴウ | ハプトグロビンの分析方法 |
| US20010046688A1 (en) * | 2000-01-28 | 2001-11-29 | Giri Brij Pal | Novel stabilized formulations for chemiluminescent assays |
| WO2009026402A1 (en) * | 2007-08-21 | 2009-02-26 | Abbott Laboratories | Measurement of haloperoxidase activity with chemiluminescent detection |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3314308A1 (de) | 1983-04-20 | 1984-10-25 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und reagens zur bestimmung des haemoglobin-haptoglobin komplexes in gegenwart von freiem haemoglobin |
| JPH02208568A (ja) | 1989-02-09 | 1990-08-20 | Green Cross Corp:The | ハプトグロビン定量試薬キット及びそれを用いるハプトグロビン定量方法 |
| US5552298A (en) * | 1992-10-23 | 1996-09-03 | Lumigen, Inc. | Enzyme-catalyzed chemiluminescence from hydroxyaryl cyclic diacylhydrazide compounds |
| US5354654A (en) * | 1993-07-16 | 1994-10-11 | The United States Of America As Represented By The Secretary Of The Navy | Lyophilized ligand-receptor complexes for assays and sensors |
| US7223552B2 (en) * | 2001-01-02 | 2007-05-29 | The Cleveland Clinic Foundation | Myeloperoxidase, a risk indicator for cardiovascular disease |
| EP1766408A2 (en) * | 2004-07-09 | 2007-03-28 | Tripath Imaging, Inc. | Methods and compositions for the detection of ovarian cancer |
| CA2574727A1 (en) * | 2004-07-19 | 2006-02-23 | University Of Rochester | Biomarkers of neurodegenerative disease |
| SG140505A1 (en) * | 2006-09-05 | 2008-03-28 | Univ Singapore | Diagnostic biomolecule(s) |
| ATE521894T1 (de) * | 2007-11-20 | 2011-09-15 | Hoffmann La Roche | Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex |
-
2010
- 2010-12-20 GB GBGB1021509.3A patent/GB201021509D0/en not_active Ceased
-
2011
- 2011-12-19 US US13/995,894 patent/US20130337481A1/en not_active Abandoned
- 2011-12-19 WO PCT/GB2011/001731 patent/WO2012085497A1/en not_active Ceased
- 2011-12-19 EP EP11811109.5A patent/EP2656082A1/en not_active Withdrawn
- 2011-12-19 JP JP2013545486A patent/JP2014501526A/ja active Pending
- 2011-12-19 CN CN201180067993.9A patent/CN103492881A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5954962A (ja) * | 1982-09-22 | 1984-03-29 | Fuji Photo Film Co Ltd | 多層分析材料 |
| JPS62192663A (ja) * | 1986-02-20 | 1987-08-24 | Fuji Photo Film Co Ltd | 免疫反応物定量用多層分析要素 |
| US6251621B1 (en) * | 1993-04-14 | 2001-06-26 | Litmus Concepts, Inc. | Reporter enzyme release technology: methods of assaying for the presence of aspartic proteases and other hydrolytic enzyme activities |
| JP2001523003A (ja) * | 1997-11-12 | 2001-11-20 | ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴウ | ハプトグロビンの分析方法 |
| US20010046688A1 (en) * | 2000-01-28 | 2001-11-29 | Giri Brij Pal | Novel stabilized formulations for chemiluminescent assays |
| WO2009026402A1 (en) * | 2007-08-21 | 2009-02-26 | Abbott Laboratories | Measurement of haloperoxidase activity with chemiluminescent detection |
Non-Patent Citations (4)
| Title |
|---|
| JPN5014002451; ＫＩＣＫＬＥＲ ＴＨＯＭＡＳ Ｓ: 'ＫＩＮＥＴＩＣ ＤＥＴＥＲＭＩＮＡＴＩＯＮ ＯＦ ＳＥＲＵＭ ＨＡＰＴＯＧＬＯＢＩＮ ＷＩＴＨ Ａ ＣＥＮＴＲＩＦＵＧＡＬ ＡＮＡＬＹＺＥＲ' ＣＬＩＮＩＣＡＬ ＣＨＥＭＩＳＴＲＹ Ｖ２２ Ｎ１２, 19761201, Ｐ１９６２-１９６７, ＡＭＥＲＩＣＡＮ ＡＳＳＯＣＩＡＴＩＯＮ ＦＯＲ ＣＬＩＮＩＣＡＬ ＣＨＥＭＩＳＴＲＹ * |
| JPN6015044425; Ｂｉｏｔｅｃｈｎｏｌ． Ｂｉｏｅｎｇ．， ２０００， ６９（３）， ｐｐ．２８６-２９１ * |
| JPN6015044429; Ｅｌｅｃｔｒｏａｎａｌ．， ２００３， １５（２２）， ｐｐ．１７３７-１７４４ * |
| JPN6015044435; Ｓｅｎｓｏｒｓ ａｎｄ Ａｃｔｕａｔｏｒｓ Ｂ， ２００８， １３０（２）， ｐｐ．９００-９０７ * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012085497A1 (en) | 2012-06-28 |
| CN103492881A (zh) | 2014-01-01 |
| US20130337481A1 (en) | 2013-12-19 |
| GB201021509D0 (en) | 2011-02-02 |
| EP2656082A1 (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501526A (ja) | アッセイ法 | |
| Morin et al. | Single Glucose Oxidase—Peroxidase reagent for two-minute determination of serum glucose | |
| JP7005785B2 (ja) | ヘモグロビンの測定試薬、測定キット及び測定方法 | |
| PL183162B1 (pl) | Sposób oznaczania glikoproteiny oraz zestaw do oznaczania glikoproteiny | |
| US9046517B2 (en) | Cystatin C adsorption inhibitor | |
| WO2013142758A1 (en) | Compositions and methods for in vitro diagnostic tests including sulfonic acid | |
| JP2014501526A5 (enExample) | ||
| CN101171518B (zh) | 铁浓度测定方法 | |
| US5563072A (en) | Method for measuring bilirubin | |
| JP4392486B2 (ja) | ハプトグロビンの分析方法 | |
| JP4214648B2 (ja) | 糖化蛋白質測定試薬 | |
| JP4580180B2 (ja) | 免疫測定法用測定値低下抑制剤及びそれを用いた免疫測定法 | |
| WO2023190087A1 (ja) | クレアチニン高値検体測定時の正確性向上 | |
| JP5294257B2 (ja) | ヘモグロビンの測定方法および測定用キット | |
| NZ582752A (en) | Combined method and kit for the sequential measurement of (1) the enzymatically active fraction via siefed and (2) the total amount of an enzyme via elisa | |
| TWI841542B (zh) | 將血紅素與血紅素結合球蛋白之複合體安定化之方法、及用以保存含有血紅素之檢體之保存溶液 | |
| JP4220765B2 (ja) | Ｄ−アミノ酸オキシダーゼの安定化方法 | |
| JPWO1996017251A1 (ja) | ビリルビンの測定方法 | |
| JP7232475B2 (ja) | ロイコ型色原体の安定化方法 | |
| CA1055825A (en) | Calibrator albumin composition | |
| JP2007212343A (ja) | 抗原の測定法およびそれに用いるキット | |
| WO2022054890A1 (ja) | 測定誤差低減方法 | |
| WO2023085323A1 (ja) | 溶血ヘモグロビンによる測定誤差を低減する方法 | |
| JP3719742B2 (ja) | ビリルビン測定用試薬および測定方法 | |
| JP2006317247A (ja) | 鉄濃度測定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141218 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141218 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151104 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160419 |